Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT06300463Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Vaccines & Immunotherapeutics, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of botensilimab, balstilimab and dalutrafusp alfa in colorectal cancer (CRC) (3 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Mean CD8:Treg ratio. Started Mar 2024; status: recruiting.
02
Drugs
botensilimabbalstilimabdalutrafusp alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06300463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300463.